The Breast Cancer Clinical Trials Consortium
Location(s): United States
The Translational Breast Cancer Research Consortium (TBCRC) was created in 2005 and comprises clinical trialists, translational scientists, and patient advocates from 14 academic medical centers dedicated to innovative, high impact and biologically-driven clinical research. The overarching mission of the Consortium is to lessen the burden of breast cancer by using a collaborative and multidisciplinary approach to improve the understanding of breast cancer biology and test new therapeutic strategies.
The Consortium conducts clinical trials in the pre-operative, pre-surgical, metastatic, and preventive settings. TBCRC members work together closely to speed completion of clinical trials, share biologic specimens and clinical data, and identify new areas for research. The successful development of improved prevention and treatment strategies requires the expertise of a collaborative group of clinical and translational scientists. The TBCRC is conducting trials that are too big for a single institution to do on its own but too small and too demanding for larger trial groups like the national cooperative groups.